Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Company Deals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

Fineline Cube Dec 18, 2025
Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025
Company Deals

HBM BMS Multi-Specific Antibody Deal Targets $1 Billion Milestones

Fineline Cube Dec 18, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor

Fineline Cube Dec 20, 2025
Company Drug

Bio‑Thera NDA for VEGF‑A165 Antibody Targets $2B Wet AMD Market in China

Fineline Cube Dec 20, 2025
Company Drug

CSPC Pharma’s rhTNK-tPA Accepted for Review by NMPA for Stroke Indication

Fineline Cube Nov 17, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that a supplementary market filing for...

Company Deals

Asia Pacific Medical Group Secures Series A Funding for Hospital Expansion

Fineline Cube Nov 17, 2022

Private healthcare group Asia Pacific Medical Group (APMG) has raised “hundreds of millions” of renminbi...

Company Drug

Haisco’s HSK31858 Gains Ethical Approval for Phase II Study in NCFBE

Fineline Cube Nov 17, 2022

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its drug candidate HSK31858...

Company Drug

CANbridge’s CAN106 Receives Orphan Drug Designation for Myasthenia Gravis

Fineline Cube Nov 17, 2022

China-based rare disease firm CANbridge Pharmaceuticals Inc. (HKG: 1228) has announced receiving Orphan Drug Designation...

Company Deals

HitGen Partners with Guangzhou AIChemEco for Automated Synthesis Technology

Fineline Cube Nov 17, 2022

China-based HitGen Inc. (SHA: 688222) has announced a partnership with compatriot firm Guangzhou AIChemEco. The...

Company

Harbour BioMed Establishes Nona Biosciences for Next-Generation Antibody Development

Fineline Cube Nov 17, 2022

Harbour BioMed (HKG: 2142), a biotech company with operations in the Netherlands, the United States,...

Company

Novartis Considers Sale of Non-Core Units to Fund Innovation

Fineline Cube Nov 17, 2022

Swiss pharmaceutical giant Novartis AG (NYSE: NVS) is reportedly considering the sale of certain ‘non-core’...

Company Deals

Sequanta Technologies Partners with Illumina to Introduce NovaSeq X Series

Fineline Cube Nov 17, 2022

Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, has entered into...

Company Drug

Ascletis Pharma’s PD-L1 Inhibitor ASC61 Gains NMPA IND Approval

Fineline Cube Nov 17, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) has announced the approval of the Investigational New Drug...

Company Deals

MicroTech Medical Plans IPO on Shanghai’s STAR Market

Fineline Cube Nov 17, 2022

China-based diabetes specialist MicroTech Medical (Hangzhou) Co., Ltd (HKG: 2235) has announced plans to conduct...

Drug

Kelun Pharma’s SKB264 Advances to Phase II Study for NSCLC

Fineline Cube Nov 16, 2022

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced that its antibody drug conjugate...

Company

Gracell’s FasTCAR Platform Wins Fierce Life Sciences Innovation Award

Fineline Cube Nov 16, 2022

China-based Gracell Biotechnologies Inc’s (Nasdaq.GRCL) FasTCAR technology platform has been named the winner of this...

Company Deals

Walvax Biotechnology Expands Manufacturing Partnership with Etana for PCV and HPV Vaccines

Fineline Cube Nov 16, 2022

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has entered into another manufacturing cooperation agreement with...

Company Deals

Simcere Pharmaceuticals Licenses Idorsia’s Insomnia Therapy Daridorexant for Greater China

Fineline Cube Nov 16, 2022

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the establishment of a licensing agreement with...

Company

Sirnaomics Announces Key Executive Promotions Effective November 15

Fineline Cube Nov 16, 2022

Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced key changes to its C-suite,...

Company Drug

Hengrui Pharmceuticals’ SHR0302 Achieves Positive Results in Phase III Atopic Dermatitis Study

Fineline Cube Nov 16, 2022

China-based Jiangsu Hengrui Pharmceuticals (SHA: 600276) has announced positive results from the randomized, double-blind, placebo-controlled,...

Company Drug

Kanghong Pharma Gains NMPA Approval for Innovative Eye Injection KH631

Fineline Cube Nov 16, 2022

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving clinical trial approvals...

Company Drug

Antengene’s ATG-008 Shows Promising Results in Cervical Cancer and Hepatocellular Carcinoma Studies

Fineline Cube Nov 16, 2022

Shanghai-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced positive preliminary results from the TORCH-2...

Company Drug

CStone Pharmaceuticals Launches AML Public Welfare Project with China Social Welfare Foundation

Fineline Cube Nov 16, 2022

The acute myeloid leukemia (AML) public welfare project, initiated by the China Social Welfare Foundation...

Company Drug

Betta Pharmaceuticals’ BPI-D0316 Accepted for NMPA Review for NSCLC Adjuvant Therapy

Fineline Cube Nov 16, 2022

China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced that its clinical trial filing for...

Posts pagination

1 … 533 534 535 … 600

Recent updates

  • BeOne Medicines Names Dual Presidents in Leadership Overhaul
  • Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline
  • TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor
  • Bio‑Thera NDA for VEGF‑A165 Antibody Targets $2B Wet AMD Market in China
  • Novo Nordisk Submits CagriSema NDA for 20% Weight Loss in Obesity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

BeOne Medicines Names Dual Presidents in Leadership Overhaul

Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Company Drug

TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor

Company Drug

Bio‑Thera NDA for VEGF‑A165 Antibody Targets $2B Wet AMD Market in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.